Drug news
No CV benefit from Contrave (bupropion and naltrexone) according to JAMA study- Orexigen
In a paper published in The Journal of the American Medical Association (JAMA) results failed to show a cardiovascular benefit for Contrave (bupropion and naltrexone) from Orexige and since it appeared that the cardiovascular safety of the drug is uncertain suggested a new adequately powered outcomes trial.
Comment: Orexigen had promoted positive early results of the trial now seen as misleading.In a editorial in JAMA a call was made for the FDA to apply a Risk Evaluation and Mitigation Strategy to Contrave.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins